alpheon
biopartners gmbh - recombinant human interferon alfa-2a - epatite c, cronica - immunostimolanti, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.
pegasys
pharmaand gmbh - peginterferone alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimolanti, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 e 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. con rispetto per la decisione di iniziare il trattamento nei pazienti in età pediatrica vedere sezioni 4. 2, 4. 4 e 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 e 5. per il virus dell'epatite c (hcv) di genotipo specifico di attività, vedere sezioni 4. 2 e 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. quando si decide di iniziare il trattamento durante l'infanzia, è importante considerare inibizione della crescita indotta dalla terapia di combinazione. la reversibilità di inibizione della crescita è incerto. la decisione di trattare deve essere fatta caso per caso (si veda la sezione 4.
somnotron 4
weinmann gerÄte fÜr medizin gmbh+co.kg - apparecchiature per pressione positiva continua
vaprino 100 mg capsule
pharma services oehler gmbh - racecadotrilum - capsule - racecadotrilum 100 mg, lactosum monohydricum 41 mg, amylum pregelificatum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: gelatina, e 172 (flavum), e 171, pro capsula. - symptomatische behandlung des akuten durchfalls bei erwachsenen über 18 jahren, sofern eine kausale therapie nicht möglich ist - synthetika
eprecis 5 mg/ml
ceva salute animale s.p.a. - eprinomectina - eprinomectina - 5 milligrammo (i), eprinomectina - 5 mg - eprinomectin
efex
ceva salute animale s.p.a. - marbofloxacina - marbofloxacina - 10 milligrammo (i), marbofloxacina - 40 milligrammo (i), marbofloxacina - 100 milligrammo (i), marbofloxacina - 10 mg, marbofloxacina - 100 mg, marbofloxacina - 40 mg - marbofloxacin
axentyl 200 mg/ml soluzione iniettabile
biovet joint stock company - tilosina - tilosina - 200 unit? internazionali/millilitro (ui/ml), tilosina - 200 unit? internazionali/millilitro (ui/ml), tilosina - 200 ui/ml - tylosin
cestem compresse aromatizzate per cani di grossa taglia
ceva salute animale s.p.a. - febantel, pirantel embonato, praziquantel - febantel - 525 milligrammo (i); pirantel embonato - 175 milligrammo (i); praziquantel - 175 milligrammo (i), praziquantel - 175 milligrammo (i); pyrantel embonato - 175 milligrammo (i); febantel - 525 milligrammo (i), praziquantel - 175 mg; pyrantel embonato - 175 mg; febantel - 525 mg, praziquantel - 175 mg; febantel - 525 mg; pyrantel embonato - 175 mg, febantel - 525 mg; pyrantel embonato - 175 mg; praziquantel - 175 mg - praziquantel, combinazioni